Wire · opportunities
Argenx digests phase 2 celiac win for $2.2B drug, preps pivotal run
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 10 October 2026 · Fusion42 review
Argenx announced positive topline results from a phase 2 trial of FB102 in celiac disease, hitting the primary endpoint and showing statistically significant improvement in villus height–to–crypt depth ratio. The biotech plans to advance FB102 into phase 3 development following its $2.2 billion acquisition of Forte Biosciences, positioning itself competitively against Teva's rival IL-15 candidate.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
You should act on FB102 entering phase 3 as it opens competitive market access versus Teva’s IL-15 drug in celiac disease. This shifts urgency to accelerate partnerships or trials before 2031 launches shape that rare disease segment.
◆ Coverage
1 source · 8 Oct 2026
◆ Related on Wire
◆ Topics